Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

ConclusionsThe safety profile of LDX in this longer-term study was similar to that reported in previous studies. The efficacy of LDX was maintained throughout the 2-year study period.ClinicalTrials.gov IdentifierNCT01328756.

Source: CNS Drugs - June 30, 2017 Category: Neurology Source Type: research